This article was originally published in The Tan Sheet
Although ingredient appears to be "very safe," corporate involvement and non-uniform endpoints in osteoarthritis studies make it difficult to recommend treatment, Paul Dieppe, et al., University of Bristol, England, say in June 16 British Medical Journal editorial. Rationale for glucosamine use is unclear and "appropriate dose and route of administration remain unknown," editorial points out. Although recent Lancet study demonstrated radiographic changes in cartilage, Dieppe et al. question whether such measures indicate long-term improvement and call for "large clinical trials, without company interference" (1"The Tan Sheet" Jan. 29, p. 4)
You may also be interested in...
Osteoarthritis patients taking glucosamine suffered no significant joint-space loss after three years, while patients given placebo demonstrated progressive joint-space narrowing, Belgian researchers report in the Jan. 27 issue of The Lancet.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning